Federal regulators say a drug from Pfizer and Ligand Pharmaceuticals effectively treats osteoporosis, though they are concerned about deaths, blood clots and other problems seen in company studies.
Osteoporosis patients given a low dose of an experimental Pfizer Inc pill were more likely to die within five years than others who got a placebo, U.S. drug reviewers said in an analysis released on Thursday.
A higher percentage of patients treated with an experimental Pfizer Inc drug for osteoporosis died during a clinical trial compared with a placebo, U.S. drug reviewers said in an analysis released on Thursday.
